Combination infliximab and tofacitinib for severe ulcerative colitis
Treatments studied
Part of Digestive system, Immune system & allergy clinical trials.
This trial tests whether giving two medicines together (infliximab and tofacitinib) is safe and effective for people hospitalized with a severe flare of ulcerative colitis. The goal is to see if the combination works better than standard care to help you recover faster.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You are currently hospitalized for a severe ulcerative colitis flare.
- You have not already been treated with tofacitinib or infliximab.
- You do not have active or latent tuberculosis (a lung infection).
- You do not have Crohn's disease or indeterminate colitis.
- You are not pregnant or breastfeeding, and you have not had blood clots or severe heart, lung, kidney, or liver problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two medications—upadacitinib and infliximab—as second-line treatments for acute severe ulcerative colitis (a serious flare of inflammatory bowel disease). The trial will help doctors understand which treatment works better when standard first-line therapy hasn't controlled the inflammation.
This study compares taking tofacitinib alone versus combining it with mesalamine to keep ulcerative colitis under control. If you are currently in remission, this trial may help find the best way to prevent flare-ups.
This study tests two drugs together, vedolizumab and tofacitinib, to see if they are more effective than either alone in treating moderate to severe ulcerative colitis. It may be an option if other treatments have not worked well for you.
This trial tests two different medicines, infliximab and upadacitinib, to see which works better for people with severe ulcerative colitis that hasn't improved after 3 days of IV steroids. The goal is to find the best rescue option to help you feel better and avoid surgery.
This study compares different sequences of medicines for treating severe ulcerative colitis flares in the hospital. It aims to find the best way to get your symptoms under control and help you feel better faster.
This trial tests whether closely monitoring and adjusting infliximab (a biologic medicine) can help people hospitalized with a moderate-to-severe flare of Crohn's disease, ulcerative colitis, or unclassified inflammatory bowel disease who haven't gotten better with IV steroids. The goal is to improve treatment response and outcomes.
Hear when a new Acute Severe Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.